🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  2. Pembrolizumab Injection

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  3. Pemetrexe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  4. Pemetrexed

    Mereo BioPharma Group plc

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  5. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, Carboplatino Aurovitas 10 mg/ml concentrado para solución para perfusión EFG, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Glenmark 10 mg/ml solución para perfusión, Carboplatino Hikma 10 mg/ml soluzione per infusione, OMTX705, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Carboplatino Teva 10 mg/ml Concentrado para solución para perfusión, Carboplatino Accord 10 mg/ml concentrado para

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.

    Fondazione Telethon ETS

    metastatic colorectal cancer

    phase 2 other active

    1 trial

  7. Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  8. Phase 1b: APG-115+pembrolizumab

    Ascentage Pharma Group

    Unresectable or Metastatic Melanoma or Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  9. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  10. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  11. Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  12. Placebo

    Spero Therapeutics

    Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

    phase 2 small molecule completed

    1 trial

  13. Placebo

    Cardiff Oncology

    Tuberous Sclerosis

    phase 2 small molecule active

    1 trial

  14. Placebo

    Takeda

    Gout

    phase 2 small molecule completed

    1 trial

  15. Placebo

    Biocryst

    Gout

    phase 2 small molecule completed

    3 trials

  16. Placebo (10 mM sodium acetate, 9.0% (w/v) sucrose, 0.02% (w/v) polysorbate 20, pH 5.2), EPINEPHRINE , Briquilimab

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  17. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  18. Placebo Oral Tablet

    Mereo BioPharma Group plc

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  19. Placebo for AMG 732 will consist of site-sourced normal saline in sterile single-use vials or ampoules, AMG 732

    Amgen

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  20. Placebo for GSK3739937 Tablets are tablets for oral administration and visually match the active GSK3739937 Tablets with the omission of the active ingredient. Placebo for GSK3739937 Tablets are white, round, film coated tablets containing no markings.

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  21. Placebo for SPT-300

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 small molecule active

    1 trial

  22. Placebo matching BLU-808, tablet, BLU-808, BLU-808

    Blueprint Medicines (Netherlands) B.V.

    Chronic Inducible Urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  23. Placebo matching REGN9933, REGN7508, REGN9933, Placebo matching REGN7508

    Lacuna Pharma Pty Ltd

    Venous Thromboembolism

    phase 2 small molecule active

    1 trial

  24. Placebo tablets are produced with the same appearance as the Valganciclovir tablets, with the same content except for the active compound., VALGANCICLOVIR

    The George Institute

    Glioblstoma WHO grade IV

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources